Platelet dysfunction associated with the novel Trp29Cys thromboxane A2 receptor variant

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 3, 2013, Pages 547-554

  Mumford, A D ^a   Nisar, S ^a   Darnige, L ^b   Jones, M L ^a   Bachelot Loza, C ^c,d   Gandrille, S ^b,c,d   Zinzindohoue, F ^b   Fischer, A M ^b,c,d   Mundell, S J ^a   Gaussem, P ^b,c,d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Platelet function disorder; TBXA2R gene; Thromboxane A2 receptor; Transmembrane domain 1

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; CALCIUM ION; COMPLEMENTARY DNA; CYSTEINE; THROMBOXANE A2 RECEPTOR; TYROSINE;

ABDOMINAL SURGERY; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CALCIUM CELL LEVEL; CASE REPORT; CELL STRAIN HEK293; CELL SURFACE; CELLULAR SECRETION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MALE; PHENOTYPE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECEPTOR GENE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; WILD TYPE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; CALCIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HEK293 CELLS; HUMANS; HYDRAZINES; LIGANDS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; PHENOTYPE; PLATELET AGGREGATION; RADIOLIGAND ASSAY; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; TRANSFECTION;

EID: 84874973640     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12117     Document Type: Article

References (26)

1. Narumiya S. Prostanoid receptors. Structure, function, and distribution. Ann N Y Acad Sci 1994; 744: 126-38.
2. 2 in vascular smooth muscle cells. Biochem Pharmacol 1990; 40: 2535-42.
3. 2 receptor. J Biol Chem 1994; 269: 19256-61.
4. 11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 1997; 281: 957-64.
5. 2 and thrombin receptors in human platelets. Proc Natl Acad Sci USA 1994; 91: 504-8.
6. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, Steinhubl SR, Becker RC. G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol 2009; 29: 449-57.
7. 2 receptor protein. J Biol Chem 2002; 277: 16791-7.
8. Dorn GW, Davis MG, D'Angelo DD. Structural determinants for agonist binding affinity to thromboxane/prostaglandin endoperoxide (TP) receptors. Analysis of chimeric rat/human TP receptors. J Biol Chem 1997; 272: 12399-405.
9. 2 receptor. Arch Biochem Biophys 2004; 423: 253-65.
10. 2 receptor: alternative role in G protein-coupled receptor signaling. Mol Pharmacol 2004; 66: 880-9.
11. 2 receptor. J Thromb Haemost 2011; 9: 1040-8.
12. 2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 1662-7.
13. 2 binding activity. Thromb Haemost 1999; 82: 1528-31.
14. 2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood 2010; 115: 363-9.
15. Mundell SJ, Jones ML, Hardy AR, Barton JF, Beaucourt SM, Conley PB, Poole AW. Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function. Mol Pharmacol 2006; 70: 1132-42.
16. Hardy AR, Conley PB, Luo J, Benovic JL, Poole AW, Mundell SJ. P2Y1 and P2Y12 receptors for adp desensitize by distinct kinase-dependent mechanisms. Blood 2005; 105: 3552-60.
17. Mundell SJ, Luo J, Benovic JL, Conley PB, Poole AW. Distinct clathrin-coated pits sort different G protein-coupled receptor cargo. Traffic 2006; 7: 1420-31.
18. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 2004; 343: 1409-38.
19. Nurden AT, Freson K, Seligsohn U. Inherited platelet disorders. Haemophilia 2012; 18: 154-60.
20. Quiroga T, Goycoolea M, Panes O, Aranda E, Martinez C, Belmont S, Munoz B, Zuniga P, Pereira J, Mezzano D. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007; 92: 357-65.
21. Daly ME, Dawood BB, Lester WA, Peake IR, Rodeghiero F, Goodeve AC, Makris M, Wilde JT, Mumford AD, Watson SP, Mundell SJ. Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood 2009; 113: 4110-13.
22. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
23. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992; 80: 2787-96.
24. 2 receptor: relevance to receptor signaling and endocytosis. Cell Signal 2005; 17: 1373-83.
25. 2 receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach. J Biol Chem 2003; 278: 10922-7.
26. Pardo L, Deupi X, Dolker N, Lopez-Rodriguez ML, Campillo M. The role of internal water molecules in the structure and function of the rhodopsin family of G protein-coupled receptors. ChemBioChem 2007; 8: 19-24.